Pulse Biosciences (NASDAQ:PLSE) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a research note released on Tuesday morning.

Pulse Biosciences Price Performance

NASDAQ PLSE opened at $18.33 on Tuesday. Pulse Biosciences has a twelve month low of $6.59 and a twelve month high of $22.69. The company’s 50-day simple moving average is $17.93 and its 200 day simple moving average is $16.66.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the prior year, the company posted ($0.19) earnings per share.

Insider Transactions at Pulse Biosciences

In related news, Director Robert W. Duggan acquired 55,256 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was purchased at an average price of $17.18 per share, for a total transaction of $949,298.08. Following the transaction, the director now directly owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. This trade represents a 0.13 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Burke Thomas Barrett sold 50,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the transaction, the chief executive officer now owns 63,172 shares in the company, valued at approximately $1,100,456.24. The trade was a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 71.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its position in shares of Pulse Biosciences by 23.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after buying an additional 9,639 shares during the period. Rhumbline Advisers grew its holdings in Pulse Biosciences by 6.7% during the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after purchasing an additional 1,608 shares during the period. Quest Partners LLC bought a new stake in Pulse Biosciences in the second quarter valued at approximately $91,000. Creative Planning boosted its position in shares of Pulse Biosciences by 113.9% during the third quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after purchasing an additional 11,667 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Pulse Biosciences by 193.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after buying an additional 97,565 shares during the period. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.